


Atty. Dkt. No. 038602-1200

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:




Claims 1 - 7 and 16 - 25 were cancelled previously.

8. (Currently amended) An indolinone compound having a structure set forth in formula (II):



wherein:

- (a) R_{11} - R_{14} are hydrogen;
- (b) R_{15} and R_{16} are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted aryl, or R_{15} and R_{16} taken together with the nitrogen atom to which they are attached form a ring structure selected from the group consisting of a five-membered or six-membered heteroaromatic ring, and a five-membered or six-membered heteroaliphatic ring, a nine-membered fused bicyclic heteroaromatic ring, and a ten-membered fused bicyclic heteroaromatic ring; and
- (c) A is selected from the group consisting of formula (III), (IV), and (V):



wherein:

- (i) R_{19} - R_{25} and R_{27} - R_{31} are hydrogen;
- (ii) R_{17} and R_{18} are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted alkoxy provided that both R_{17} and R_{18} are not hydrogen; and
- (iii) R_{26} is selected from the group consisting of optionally substituted alkyl; or a pharmaceutically acceptable salt thereof.

Atty. Dkt. No. 038602-1200

9. (Currently amended) The compound of claim 8, wherein:

- (i) R₁₅ is hydrogen or alkyl;
- (ii) R₁₆ is hydrogen, alkyl, or phenyl, wherein said phenyl group is optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl; or R₁₅ and R₁₆ together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl;
- (iii) R₁₇ is hydrogen, methyl, or methoxy;
- (iv) R₁₈ is selected from the group consisting of lower alkoxy substituted with heteroalicyclic; and
- (v) A is group of formula III.

10. (Currently amended) The compound of claim 8, wherein:

- (i) R₁₅ is hydrogen or methyl;
- (ii) R₁₆ is hydrogen, methyl, isopropyl, phenyl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl; or R₁₅ and R₁₆ together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl;
- (iii) R₁₇ is selected from the group consisting of hydrogen, methyl, and methoxy; and
- (iv) R₁₈ is selected from the group consisting of hydrogen, 2-pyrrolidin-1-yl-ethoxy and 2-morpholin-4-yl-ethoxy;

11. (Currently amended) The compound of claim 8, wherein:

- (i) R₁₅ is hydrogen or alkyl;
- (ii) R₁₆ is hydrogen, alkyl, or phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl; or
- ~~(iii) R₁₅ and R₁₆ together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl;~~
- (iii) R₂₆ is selected from the group consisting of optionally substituted alkyl; and
- (iv) A is group of formula IV.

Atty. Dkt. No. 038602-1200

12. (Currently amended) The compound of claim 8, wherein:

(i) R_{15} is hydrogen or methyl;

(ii) R_{16} is hydrogen, methyl, isopropyl, phenyl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl; or R_{15} and R_{16} together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isosequinolin-2-yl; and

(iii) R_{26} is methyl.

13. (Currently amended) The compound of claim 8, wherein:

(i) R_{15} is hydrogen or alkyl;

(ii) R_{16} is hydrogen, alkyl, phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl; or R_{15} and R_{16} together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isosequinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl; and

(iii) A is group of formula V.

14. (Currently amended) The compound of claim 8, wherein:

(i) R_{15} is hydrogen or methyl; and

(ii) R_{16} is hydrogen, methyl, isopropyl, phenyl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl; or R_{15} and R_{16} together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isosequinolin-2-yl; and

(iii) A is group of formula V.

15. (Currently amended) A compound selected from the group consisting of:

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1H-indol-2-ylmethylene]-2,3-dihydro-1H-indole-5-sulfonic acid amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1H-indol-2-ylmethylene]-2,3-dihydro-1H-indole-5-sulfonic acid methylamide,

Atty. Dkt. No. 038602-1200

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
 2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,
 2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,
~~5-(2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
 2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,
 2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-methyl-amide,
 2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,
~~5-(3,4-dihydro-2*H*-quinoline-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
~~5-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
~~5-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
 3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,
 3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
 3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,
 3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,
~~5-(2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

Atty. Dkt. No. 038602-1200

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,
3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-methyl-amide,
3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,
~~5-(3,4-dihydro-2*H*-quinoline-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
~~5-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
~~5-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~
3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,
3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,
3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,
3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,
3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,
3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,
3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,
3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
and 3-(4-methoxy-1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide;
or a pharmaceutically acceptable salt thereof.